PSORIASIS VULGARIS
Clinical trials for PSORIASIS VULGARIS explained in plain language.
Never miss a new study
Get alerted when new PSORIASIS VULGARIS trials appear
Sign up with your email to follow new studies for PSORIASIS VULGARIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Higher dose tested for psoriasis patients who weigh more
Disease control CompletedThis study tested if a higher dose of the drug brodalumab works better for people with moderate-to-severe plaque psoriasis who weigh 120 kg (265 lbs) or more. It involved 385 adults and compared the standard treatment to an increased dosage given by injection every two weeks. The…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Apr 04, 2026 03:51 UTC
-
Can psoriasis patients safely cut their biologic doses in half?
Disease control CompletedThis study investigated whether patients with stable, mild psoriasis could safely reduce the dose of their advanced biologic medications (IL-17 or IL-23 inhibitors) without their symptoms getting worse. 244 patients who had been doing well on standard doses were randomly assigned…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE4 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Natural cream tested for stubborn skin condition
Disease control CompletedThis study tested whether a cream made from plant compounds called coumarins could help control plaque psoriasis. 88 adults with mild to moderate psoriasis applied either the cream or a placebo for 8 weeks. Researchers measured changes in skin redness, thickness, scaling, and how…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE2 • Sponsor: Psoriasis Research Institute of Guangzhou • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Light-Activated gel shows promise for psoriasis skin relief
Disease control CompletedThis study tested a new topical ointment called SGX302, which is activated by visible light, to see if it could improve skin lesions in people with mild-to-moderate plaque psoriasis. Fifteen participants applied the treatment to their skin for an 18-week course. The main goal was…
Matched conditions: PSORIASIS VULGARIS
Phase: PHASE2 • Sponsor: Soligenix • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC